Literature DB >> 30514793

CD16+NKG2Ahigh Natural Killer Cells Infiltrate Breast Cancer-Draining Lymph Nodes.

Alexandra Frazao1,2, Meriem Messaoudene1,3, Nicolas Nunez4,5, Nicolas Dulphy1,2,6, France Roussin7, Christine Sedlik4,5, Laurence Zitvogel3,8,9,10, Eliane Piaggio4,5, Antoine Toubert1,2,6, Anne Caignard11.   

Abstract

Tumor-draining lymph nodes (TD-LNs) are the first site of metastasis of breast cancer. Natural killer (NK) cells that infiltrate TD-LNs [including noninvaded (NI) or metastatic (M)-LNs from breast cancer patients] and NK cells from healthy donor (HD)-LNs were characterized, and their phenotype analyzed by flow cytometry. Low percentages of tumor cells invaded M-LNs, and these cells expressed ULBP2 and HLA class I molecules. Although NK cells from paired NI and M-LNs were similar, they expressed different markers compared with HD-LN NK cells. Compared with HD-LNs, TD-LN NK cells expressed activating DNAM-1, NKG2C and inhibitory NKG2A receptors, and exhibited elevated CXCR3 expression. CD16, NKG2A, and NKp46 expression were shown to be increased in stage IIIA breast cancer patients. TD-LNs contained a large proportion of activated CD56brightCD16+ NK cells with high expression of NKG2A. We also showed that a subset of LN NK cells expressed PD-1, expression of which was correlated with NKp30 and NKG2C expression. LN NK cell activation status was evaluated by degranulation potential and lytic capacity toward breast cancer cells. NK cells from TD-LNs degranulated after coculture with breast cancer cell lines. Cytokine-activated TD-LN NK cells exerted greater lysis of breast cancer cell lines than HD-LN NK cells and preferentially lysed the HLA class Ilow MCF-7 breast cancer cell line. TD-LNs from breast cancer patients, thus, contained activated lytic NK cells. The expression of inhibitory receptor NKG2A and checkpoint PD-1 by NK cells infiltrating breast cancer-draining LNs supports their potential as targets for immunotherapies using anti-NKG2A and/or anti-PD-1. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30514793     DOI: 10.1158/2326-6066.CIR-18-0085

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  14 in total

Review 1.  The role of the natural killer (NK) cell modulation in breast cancer incidence and progress.

Authors:  Ehsan Razeghian; Mahdis Chahar Kameh; Sepehr Shafiee; Farima Khalafi; Fehimeh Jafari; Mohammadali Asghari; Kiarash Kazemi; Saba Ilkhani; Siavash Shariatzadeh; Arvin Haj-Mirzaian
Journal:  Mol Biol Rep       Date:  2022-08-25       Impact factor: 2.742

Review 2.  Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy.

Authors:  Sebastian Chrétien; Ioannis Zerdes; Jonas Bergh; Alexios Matikas; Theodoros Foukakis
Journal:  Cancers (Basel)       Date:  2019-05-05       Impact factor: 6.639

Review 3.  The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.

Authors:  Haoyu Sun; Cheng Sun
Journal:  Front Immunol       Date:  2019-10-17       Impact factor: 7.561

Review 4.  The Multifaceted Effects of Breast Cancer on Tumor-Draining Lymph Nodes.

Authors:  Samir Jana; Ronald A Muscarella; Dennis Jones
Journal:  Am J Pathol       Date:  2021-05-24       Impact factor: 5.770

Review 5.  Tissue-Resident NK Cells: Development, Maturation, and Clinical Relevance.

Authors:  Elaheh Hashemi; Subramaniam Malarkannan
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

6.  Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.

Authors:  Maite Alvarez; Federico Simonetta; Jeanette Baker; Alyssa R Morrison; Arielle S Wenokur; Antonio Pierini; Pedro Berraondo; Robert S Negrin
Journal:  Front Immunol       Date:  2020-02-11       Impact factor: 7.561

7.  Bioinformatic profiling of prognosis-related genes in the breast cancer immune microenvironment.

Authors:  Fang Bai; Yuchun Jin; Peng Zhang; Hongliang Chen; Yipeng Fu; Mingdi Zhang; Ziyi Weng; Kejin Wu
Journal:  Aging (Albany NY)       Date:  2019-11-12       Impact factor: 5.682

Review 8.  Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?

Authors:  Aviad Ben-Shmuel; Guy Biber; Mira Barda-Saad
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

Review 9.  Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.

Authors:  Yuqing Cao; Xiaoyu Wang; Tianqiang Jin; Yu Tian; Chaoliu Dai; Crystal Widarma; Rui Song; Feng Xu
Journal:  Signal Transduct Target Ther       Date:  2020-10-29

Review 10.  A Rosetta Stone for Breast Cancer: Prognostic Value and Dynamic Regulation of Neutrophil in Tumor Microenvironment.

Authors:  Wei Zhang; Yimin Shen; Huanhuan Huang; Sheng Pan; Jingxin Jiang; Wuzhen Chen; Ting Zhang; Chao Zhang; Chao Ni
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.